SPONSOR:PRINTER'S NO.

Sen.1712 THE GENERAL ASSEMBLY OF PENNSYLVANIA SENATE RESOLUTION Session of No.

Poore314 &2026 Rep.INTRODUCED BY COLLETT, HUGHES, HAYWOOD, TARTAGLIONE, COSTA, PHILLIPS-HILL, SANTARSIERO, CAPPELLETTI, VOGEL, KANE, PISCIOTTANO AND STREET, MAY 7, 2026 REFERRED TO RULES AND EXECUTIVE NOMINATIONS, MAY 7, 2026 A RESOLUTION Designating the week of May 4 through 10, 2026, as "Tardive Dyskinesia Awareness Week" in Pennsylvania.

Minor-BrownWHEREAS, Sens.Many individuals living with serious mental illnesses, including schizophrenia and other schizoaffective disorders, bipolar disorder and major depressive disorder, require treatment with antipsychotic medications for effective management, and antipsychotic prescribing rates in the United States continue to rise;

Hansen,and Pinkney;WHEREAS, While ongoing treatment with antipsychotic medications can be necessary, prolonged use is associated with Tardive Dyskinesia (TD);

Reps.and WHEREAS, TD is a movement disorder characterized by uncontrollable, abnormal and repetitive movements of the face, torso, limbs and extremities;

Briggsand King,WHEREAS, Griffith,TD K.can develop months, years or decades after an individual starts taking antipsychotic medications and may persist even after the individual has discontinued use of those medications;

Johnsonand DELAWAREWHEREAS, STATEEven SENATEmild 152ndsymptoms GENERALof ASSEMBLYTD SENATEcan CONCURRENTbe RESOLUTIONstigmatizing NO.and impair physical, social and emotional well-being;

33and DESIGNATINGWHEREAS, MAYIndividuals 1–7,at 2023,higher ASrisk “TARDIVEof DYSKINESIATD AWARENESSinclude WEEK”those INover DELAWARE.55 years of age, Black individuals, women, individuals with mood or substance use disorders, individuals with intellectual disabilities or central nervous system injuries and those with high cumulative exposure to antipsychotic medications;

and WHEREAS, MayIt is Nationalestimated Mentalthat Health800,000 Awarenessadults Month;in the United States are living with TD, and approximately 60% of those individuals remain undiagnosed;

and WHEREAS, TardiveThe DyskinesiaAmerican isPsychiatric aAssociation movementrecommends disorderroutine thatTD disproportionatelyscreening affectsas peoplepart beingof treatedits forclinical chronicpractice mentalguideline healthfor conditions,the includingtreatment schizophrenia,of bipolarpatients disorder,receiving andantipsychotic severemedications; depression;

and WHEREAS, ongoingTreatments treatmentapproved withby prescriptionthe antipsychoticUnited medicationsStates hasFood manyand benefitsDrug Administration for thoseTD withcan theseprovide options for symptom management and otherimproved mentalquality illnesses;of life for many individuals living with TD;

and WHEREAS, antipsychoticTD medicationsis mayoften leadunrecognized toand Tardiveindividuals Dyskinesialiving inwith onethe outcondition ofare everycommonly fourmisdiagnosed, patientsunderscoring receivingthe long-termurgency treatment;of early screening, detection and intervention;

and WHEREAS, TardiveThe DyskinesiaSenate iscan characterizedraise byawareness random,of involuntary,TD andamong uncontrollablethe movementspublic, of muscles in the face,medical trunk,community, patients and extremities;care partners;

andtherefore WHEREAS,be Tardiveit DyskinesiaRESOLVED, canThat developthe longSenate afterdesignate athe personweek beginsof treatment,May or4 eventhrough after10, the2026, discontinuationas of"Tardive treatmentDyskinesia withAwareness antipsychoticWeek" medications;in Pennsylvania;

and WHEREAS,be onceit Tardivefurther DyskinesiaRESOLVED, develops,That itthe isSenate oftenunderscore permanent;the importance of early detection and intervention to improve outcomes for individuals 20260SR0314PN1712 - 2 - living with mental health conditions who are prescribed antipsychotic medications, and support efforts to raise awareness about the causes and symptoms of TD and the importance of routine TD screening;

and WHEREAS,be overit 600,000further AmericansRESOLVED, haveThat beenthe diagnosedSenate withencourage Tardiveanyone Dyskinesia,experiencing withuncontrollable, manyabnormal moreand suffering,repetitive althoughmovements unawareto ofconsult thetheir causehealth orcare havingprovider beenregarding misdiagnosed;their symptoms.

and20260SR0314PN1712 WHEREAS,- scientific3 breakthroughs- and years of research have allowed the Food and Drug Administration to recently approve two new treatments for the symptoms related to Tardive Dyskinesia;

and WHEREAS, it is important to raise further awareness of this disorder throughout the community.

NOW, THEREFORE:

BE IT RESOLVED by the Senate of the 152nd General Assembly of the State of Delaware, the House of Representatives concurring therein, that the week of May 1-7, 2023, is designated as “Tardive Dyskinesia Awareness Week” in the State of Delaware.

BE IT FURTHER RESOLVED that this General Assembly encourages all Delawareans to become better informed about Tardive Dyskinesia.

SD :

AVP :

CBK Page 1 of 2 Released:

04/05/2023 02:16 PM SYNOPSIS This resolution designates the week of May 1-7, 2023, as "Tardive Dyskinesia Awareness Week" in Delaware.

Author:

Senator Poore SD :

AVP :

CBK Page 2 of 2 Released:

04/05/2023 02:16 PM 4761520022